The new facility will help biotechnology and pharmaceutical partners validate technologies and accelerate next-generation diagnostics from concept to commercialization.
ARUP Laboratories has launched an Innovation Central Laboratory designed to facilitate collaboration with pharmaceutical, biotechnology, and other industry partners in developing next-generation diagnostic technologies.
The Salt Lake City-based nonprofit reference laboratory says the new facility will serve as an ecosystem for validating technologies and accelerating diagnostics from concept to commercialization.
“The Innovation Central Laboratory represents a bold step forward in diagnostic medicine,” says Tracy George, MD, ARUP chief scientific officer and president of ARUP’s Innovation Business Unit, in a release. “By building and validating tests that are truly commercial-ready, we’re not just accelerating innovation, we’re ensuring that groundbreaking diagnostics can be adopted in real-world laboratories to improve patient care globally.”
Full Suite of Development Services
The Innovation Central Laboratory leverages ARUP’s clinical, scientific, and regulatory expertise to provide partners with early-stage exploration and refinement of novel diagnostic concepts outside of routine clinical workflows. ARUP offers full life cycle management services to help partners accelerate innovation and bring products to market.
Current initiatives include developing assays for rare and underrecognized diseases, improving genomic sequencing technologies, operationalizing artificial intelligence and digital pathology solutions into laboratory workflows, and facilitating biomarker discovery for neurodegenerative diseases.
Recent Innovation Developments
The launch follows several recent innovative developments from ARUP. In April 2025, the laboratory launched a blood-based biomarker assay to determine whether cognitive decline symptoms in patients ages 60 years and older are related to Alzheimer’s disease pathology. Blood-based biomarkers provide a more accessible and less invasive diagnostic tool than standard methods such as amyloid positron emission tomography imaging.
ARUP has also partnered with Tasso Inc to develop at-home blood testing services for clinical research support. The laboratory has validated several assays using capillary blood microsamples collected with the Tasso device and will serve as the performing laboratory for the combined service.
The laboratory’s central pathology review service has supported clinical trials, including a therapy for patients with nonadvanced systemic mastocytosis.
ARUP offers more than 3,000 tests and test combinations, ranging from routine screening tests to molecular and genetic assays. The laboratory is ISO 15189- and College of American Pathologists-accredited.
Photo caption: Leaders of ARUP’s Innovation Business Unit discuss their latest developments. Pictured from left to right are Hunter Best, PhD, FACMG; Tracy George, MD; Erica Clyde, MBA, PMI-PMP, MB(ASCP)CM; and Salika Shakir, PhD, D(ABMM).
Photo credit: ARUP Laboratories
